Celltrion Pharm, Inc. (KOSDAQ:068760)

Market Cap	2.31T
Revenue (ttm)	274.73B
Net Income (ttm)	26.03B
Shares Out	43.49M
EPS (ttm)	595.02
PE Ratio	89.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,075
Average Volume	130,742
Open	52,900
Previous Close	53,000
Day's Range	52,700 - 53,400
52-Week Range	44,500 - 80,571
Beta	1.50
RSI	49.66
Earnings Date	n/a

About MorphoSys AG

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1976
• Employees: 328
• Stock Exchange: KOSDAQ
• Ticker Symbol: 068760

Financial Performance

In 2020, Celltrion Pharm's revenue was 233.57 billion, an increase of 34.61% compared to the previous year's 173.51 billion. Earnings were 20.94 billion, an increase of 143.42%.